Hence, the classic advice is that traditional (nonselective) Na+ channel‐blocking ASMs should not be used in Dravet syndrome, the most common etiology of which is impairment in Nav1.1 resulting in impaired inhibition. The gene discussed is SCN1A; the disease is Dravet syndrome.